Penumbra Inc logo

Penumbra Inc(PEN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 18 days
PROFIT SINCE LAST BUY
-0.82% ▼
LAST CLOSE
$320.91
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PEN

11/13/2026: PEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Penumbra Inc is a specialized medical device company recognized for its role in developing minimally invasive thrombectomy technology for neurovascular and peripheral vascular conditions. The company's growth is fueled by a commitment to physician-led innovation and a robust, vertically integrated business model. Its primary investment story centers on the continued global adoption of its proprietary computer-assisted vacuum technology. However, Penumbra faces significant risks from well-capitalized competitors, pricing pressure from healthcare systems, and the need for ongoing positive clinical results. The stock may suit growth-oriented investors who can tolerate volatility, while those seeking dividends or low-risk stability will likely find the company's investment profile a poor fit.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitPenumbra consistently prioritizes high-growth medical technology sectors and reinvests heavily in innovation.
Momentum investorStrong fit while signal remains positiveThe stock often reacts strongly to new clinical data or commercial adoption signals for its thrombectomy products.
Value investorWeak fitThe company typically trades at high valuation multiples consistent with high-growth medical device stocks.
Dividend investorWeak fitPenumbra does not pay dividends and focuses all capital on business expansion.
Low-risk investorWeak fitThe stock experiences significant volatility associated with its growth valuation and healthcare sector risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highHigh growth expectations can lead to sharp price swings based on quarterly earnings or regulatory updates.
Valuation riskMedium / highThe stock's premium valuation leaves little margin for error regarding revenue growth performance.
Competition risk (Medical Technology)HighLarge incumbents like Medtronic and Stryker have deep pockets to challenge Penumbra's market position.
Business qualityStrongThe company possesses a strong reputation for proprietary, high-quality medical device engineering.
Dividend incomeLow / noneInvestors should not rely on Penumbra for steady income as all cash is reinvested.
Execution riskMediumSuccessful commercialization depends on consistent physician adoption and ongoing hospital training.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 12.65B USD
Price to earnings Ratio 80.83
1Y Target Price 362.54
Price to earnings Ratio 80.83
1Y Target Price 362.54
Volume (30-day avg) 375.3K shares
Beta 0.69
52 Weeks Range 276.01 - 362.41
Updated Date 11/14/2026
52 Weeks Range 276.01 - 362.41
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 3.97

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Very Smooth
PRICE STABILITY

Very Smooth

The stock has followed a highly orderly price path with minimal short-term disruption.

Analysis of Past Performance

Type Stock
Historic Profit -4.6%
Avg. Invested days 41
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PEN receives a 4-star rating, supported by solid unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
PEN has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and strong ownership. In FY2025 versus FY2024, strong earnings growth (+1168.1%) supports the fundamentals score.

Financial Health Rating

★★★★★
PEN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 56.6%). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is PEN's strongest growth driver at +1168.1% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+17.5%, solid) and free-cash-flow growth (+18.8%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 87.1% and approximately 97.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.63% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.90%
HBK INVESTMENTS L P 4.66%
Vanguard Capital Management, LLC 4.34%
Vanguard Portfolio Management, LLC 4.23%
State Street Corp 3.15%

Unit Economics (Per $1K Revenue)

★★★★★
PEN generates approximately $671 of gross profit, $135 of operating income, and $125 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and solid cash conversion support the rating, although capital efficiency remains moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 13.38%

Quantitative Style Profile

★★★★★
PEN has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltLow VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Neurovascular ProductsCatheters, coils, and access devices for stroke and brain-related vascular procedures.Revenue is earned by selling advanced tools doctors use to treat life-threatening strokes.
Peripheral Vascular ProductsLightning aspiration systems for removing clots in arms, legs, and lungs.This is a key area of expansion, targeting common issues like deep vein thrombosis.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 1.21
Actual 1.07

Profitability

Profit Margin 10.06%
Operating Margin (TTM) 12.13%

Management Effectiveness

Return on Assets (TTM) 6.28%
Return on Equity (TTM) 10.67%

Valuation

Trailing PE 80.83
Forward PE 55.87
Enterprise Value 12.18B
Price to Sales(TTM) 8.11
Enterprise Value 12.18B
Price to Sales(TTM) 8.11
Enterprise Value to Revenue 7.81
Enterprise Value to EBITDA 53.13
Shares Outstanding 39.41M
Shares Floating 38.30M
Shares Outstanding 39.41M
Shares Floating 38.30M
Percent Insiders 6.63
Percent Institutions 87.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.